Research programme: antibacterials - Kyorin/Merck
Alternative Names: AM 7359; AM 7383Latest Information Update: 24 Aug 2011
At a glance
- Originator Kyorin Pharmaceutical; Merck & Co
- Class Oxazolidinones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 24 Aug 2011 No development reported - Preclinical for Bacterial infections in Japan (unspecified route)
- 24 Aug 2011 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 22 Feb 2007 Preclinical development is ongoing